Results were that incidence of biliary disease, i.e., conditions that effect the gallbladder/bile ducts, (per 1,000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide (another GLP-1 agonist), and 12.6 for bupropion-naltrexone and 4.6, 7.9 and 1.0, respectively, for pancreatitis
Key points Endocrine-disrupting chemicals of various sources, classifications and mechanisms of actions might promote prostate cancer development
"There will be a small proportion of people, 10% maximum, that are able to maintain [all] the weight they've lost," says Alex Miras, a clinical professor of medicine at Ulster University
There are multiple FDA-approved and affordable prescription options available, including alternatives for those no longer able to access compounded semaglutide or tirzepatide